At iTeos, we believe that collaboration is critical to achieve our mission of developing breakthrough therapies.
We work together to develop breakthrough therapies to treat cancer through improving the immune response.
We have built a Board composed of the different talents to support the growth and differentiation of iTeos as a leader in development of the next generation of cancer immunotherapies by combining expertise in immuno-oncology, clinical strategy, company builders, corporate strategy, finance and commercialization.
iTeos’ Scientific Advisory Board board provides an external scientific review of R&D activities and assists us in making significant scientific judgments related to R&D activities and portfolio management and prioritization.
